Today: 11 April 2026
Subscribe
Browse Category

Pharmaceuticals 30 October 2025 - 6 November 2025

Moderna (MRNA) Beats Q3 on Sales of New COVID Shot, Trims 2025 Outlook; Stock Whipsaws — Nov. 6, 2025

Moderna (MRNA) Beats Q3 on Sales of New COVID Shot, Trims 2025 Outlook; Stock Whipsaws — Nov. 6, 2025

Moderna reported Q3 2025 revenue of $1.02 billion and a GAAP loss of $0.51 per share, both ahead of analyst forecasts, driven by $971 million in COVID-19 vaccine sales. The company narrowed its full-year revenue outlook to $1.6–$2.0 billion, cut operating-expense guidance by $700 million, and raised its year-end cash target. Shares rose pre-market but traded unevenly during the session.
6 November 2025
··
Pfizer (PFE) Stock at a Crossroads: Big Dividend, Weight-Loss Gamble & 2025 Outlook

Pfizer (PFE) today: Court denies bid to block Novo–Metsera deal; Pfizer preps sweeter offer and leans on higher 2025 EPS outlook

A Delaware court denied Pfizer’s request to block Metsera from ending their merger deal in favor of Novo Nordisk’s higher bid. Pfizer plans to raise its offer after Novo’s proposal reached up to $10 billion. FTC staff warned Novo’s bid structure could violate pre-merger rules. Pfizer shares traded near $24.61 midday Thursday.
6 November 2025
····
Pfizer Stock Plunge and Promise: Vaccine Slump, Weight-Loss War, and a $10B Gamble – Is PFE Poised for a Comeback?

Pfizer Stock Plunge and Promise: Vaccine Slump, Weight-Loss War, and a $10B Gamble – Is PFE Poised for a Comeback?

Pfizer closed at $24.45 on Nov. 5, 2025, with a market cap near $138 billion, more than 60% below its pandemic-era peak. Q3 revenue fell 6% to about $16.7 billion, while adjusted earnings beat forecasts at $0.87 per share. COVID-19 product sales continued to drop sharply. Pfizer is in a bidding war with Novo Nordisk for obesity drug developer Metsera.
5 November 2025
··
Biohaven (BHVN) Stock Plunges on FDA Setback – Will Its Biotech Pipeline Fuel a Comeback?

Biohaven (BHVN) Stock Plunges on FDA Setback – Will Its Biotech Pipeline Fuel a Comeback?

Biohaven Ltd. shares plunged about 40% on Nov. 5, 2025, after the FDA rejected its lead drug VYGLXIA for spinocerebellar ataxia, citing trial design and data issues. The company will cut R&D spending by 60% and halt non-priority programs. Analysts downgraded the stock, which now trades near $8–9, down over 70% year-over-year. Biohaven reported a $198 million net loss in Q2 with $408 million in cash.
5 November 2025
·
Teva Stock Soars on Earnings Beat: Inside Teva’s 2025 Comeback and What’s Next for Investors

Teva Stock Soars on Earnings Beat: Inside Teva’s 2025 Comeback and What’s Next for Investors

Teva Pharmaceutical reported Q3 2025 adjusted EPS of $0.78 on $4.48 billion revenue, beating estimates and sending shares up 10–11% to a new 52-week high. The company raised 2025 guidance, citing strong sales of Austedo and other branded drugs, and Fitch upgraded its credit rating in May. Debt fell to $16.79 billion. Teva’s forward P/E remains below industry averages despite the stock’s sharp recovery.
5 November 2025
···
Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Novo Nordisk’s Weight-Loss Drug Boom Hits a Wall – Wegovy Slowdown Sparks Stock Slump and Forecast Cut

Novo Nordisk cut its 2025 sales and profit outlook for the fourth time this year after third-quarter results missed forecasts, with Wegovy revenues below expectations. Operating profit fell 30% due to restructuring costs. The company faces rising competition from Eli Lilly and U.S. copycat drugs, as well as mounting pricing pressure. Shares have dropped up to 50% in 2025; Novo plans 9,000 job cuts and a $10 billion bid for Metsera.
5 November 2025
···
Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Novo Nordisk raised its offer for Metsera to about $10 billion, topping Pfizer’s $8.1 billion bid. Metsera’s board labeled Novo’s bid “superior,” triggering a two-day window for Pfizer to respond. Pfizer has filed lawsuits in Delaware and federal court to block Novo’s challenge. Shares in Metsera jumped 20% after the news, while Novo’s stock slipped.
4 November 2025
···
Fentanyl ‘Nuke’ & Anti-Woke Crusade: Palantir CEO’s Wild Earnings Call Fuels $490 B AI Surge

Fentanyl ‘Nuke’ & Anti-Woke Crusade: Palantir CEO’s Wild Earnings Call Fuels $490 B AI Surge

Palantir Technologies reported Q3 2025 revenue of nearly $1.2 billion, up 63% year-on-year, and raised full-year guidance to $4.4 billion. CEO Alex Karp declared Palantir “the first company to be completely anti-woke,” defended its work with ICE and Israel, and told critics to “get some popcorn.” Shares surged 200% in 2025 but fell 7% after earnings on valuation concerns.
4 November 2025
··
Pfizer’s Q3 Shocker: Earnings Beat, Outlook Raised, and a $7 Billion Obesity Drug Gambit

Pfizer’s Q3 Shocker: Earnings Beat, Outlook Raised, and a $7 Billion Obesity Drug Gambit

Pfizer reported Q3 2025 adjusted earnings of $0.87 per share, beating estimates, with revenue at $16.65–$16.7 billion. The company raised its full-year profit outlook to $3.00–$3.15 EPS. Sales of COVID products plunged, but demand for Eliquis and Vyndaqel rose. Pfizer sued Novo Nordisk over a $7.3 billion bid for obesity drugmaker Metsera; a court hearing is set for Nov. 4.
4 November 2025
···
Pfizer (PFE) Stock at a Crossroads: Big Dividend, Weight-Loss Gamble & 2025 Outlook

Pfizer (PFE) Stock at a Crossroads: Big Dividend, Weight-Loss Gamble & 2025 Outlook

Pfizer shares traded at $24.65 on Nov. 3, 2025, down about 3% year-to-date and over 50% from pandemic highs. The company reports Q3 results Nov. 4, with analysts expecting $16.6 billion in revenue and $0.66 EPS. Pfizer completed a $43 billion Seagen acquisition and is in a bidding war with Novo Nordisk over Metsera. The quarterly dividend is $0.43 per share, yielding around 7%.
3 November 2025
··
Rani Therapeutics (RANI) Stock Skyrockets on Biotech Breakthrough: Inside the Surge and What’s Next

Rani Therapeutics (RANI) Stock Skyrockets on Biotech Breakthrough: Inside the Surge and What’s Next

Rani Therapeutics shares surged over 300% in a month, jumping to $2.20–$2.50 after announcing a partnership with Chugai Pharmaceutical worth up to $1.085 billion. The deal brought $10 million upfront and extended Rani’s cash runway into 2028 with a $60.3 million financing. Analyst targets rose as high as $11. Trading volume spiked tenfold, with the stock breaking key technical levels.
3 November 2025
··
Pfizer Stock Surges on Trump Deal & Obesity Drug Drama – Is a Comeback Coming?

Pfizer Stock Surges on Trump Deal & Obesity Drug Drama – Is a Comeback Coming?

Pfizer shares closed at $24.65 on Oct. 31, 2025, rebounding from September lows after a White House drug pricing deal but still near multi-year lows. The company is suing Novo Nordisk over an $8.5 billion bid for obesity drugmaker Metsera, which undercut Pfizer’s own $7.3 billion offer. Investors await Pfizer’s Q3 earnings on Nov. 4 as the firm faces a sharp drop in COVID-related sales.
2 November 2025
·
Eli Lilly Stock Pre-Market Preview: Will Obesity-Drug Boom Send LLY to New Highs? (Nov 3, 2025)

Eli Lilly Stock Pre-Market Preview: Will Obesity-Drug Boom Send LLY to New Highs? (Nov 3, 2025)

Eli Lilly shares closed near $863 on Oct. 31, up about 10% for the month and close to a 52-week high. Q3 revenue jumped 54% to $17.6 billion, driven by surging demand for GLP-1 drugs Mounjaro and Zepbound, with U.S. GLP-1 market share at 57%. Management raised 2025 sales and EPS guidance sharply. The company recently won FDA approval for Inluriyo and expanded Walmart access for Zepbound.
2 November 2025
·
Rani Therapeutics (RANI) Stock Skyrockets ~200% on $1B Pharma Deal – Will the Rally Last?

Rani Therapeutics Stock Explodes on Obesity-Drug Breakthrough – Analysts Eye $10+ Targets

Rani Therapeutics stock surged 330% in October, closing at $2.20 on Nov. 1 after announcing a $1.085 billion licensing deal with Chugai and positive preclinical data for its oral semaglutide pill. The company, which has no approved products or meaningful revenue, raised $60.3 million in a private placement. Analysts rate RANI a Buy, but warn of high risk due to ongoing losses and no product sales.
1 November 2025
·
AbbVie’s Bull Run: Why This $400B Pharma Giant’s Stock Is Just Getting Started

AbbVie’s Bull Run: Why This $400B Pharma Giant’s Stock Is Just Getting Started

AbbVie reported Q3 2025 revenue of $15.78 billion, up 9.1% year-over-year, and raised its full-year EPS outlook after new drugs offset Humira’s decline. Shares traded near $228 in late October, up 28% year-to-date, and the board approved a 5.5% dividend increase for 2026. Skyrizi and Rinvoq sales surged, while the FDA expanded Rinvoq’s indications. AbbVie also announced over $10 billion in acquisitions and new manufacturing investments.
31 October 2025
··
Moderna Stock Soars on Buyout Buzz – Can New Vaccines Fuel a Comeback?

Moderna Stock Soars on Buyout Buzz – Can New Vaccines Fuel a Comeback?

Moderna shares surged 12% to near $27.50 on Oct. 30, 2025, after reports of takeover talks with a large drugmaker. The rally follows a STAT News report on possible deals, but Moderna declined comment. Despite gains, the stock remains down about 37% year-to-date. Recent FDA approvals include updated COVID and RSV vaccines, but falling COVID demand has cut 2025 revenue and forced cost reductions.
30 October 2025
··
Pfizer Stock Soars: Trump’s Drug-Price Deal and $7B Weight-Loss Bet Spark Rally

Pfizer Stock Soars: Trump’s Drug-Price Deal and $7B Weight-Loss Bet Spark Rally

Pfizer shares traded near $24.20 on Oct. 30, 2025, flat for the week and close to the low end of their 52-week range. The stock surged 15% in late September after Pfizer agreed to cut Medicaid drug prices and announced a $7.3 billion deal to acquire obesity-drug maker Metsera. Rival Novo Nordisk countered with a higher bid for Metsera. Q3 earnings are due Nov. 4, with analysts expecting a sharp year-over-year decline.
30 October 2025
··
Novo Nordisk (NVO) Stock Tanks as Weight-Loss Empire Faces Boardroom Coup and Fierce Rivalry

Novo Nordisk hijacks Pfizer’s Metsera deal with a $9B bid – obesity-drug war heats up

Novo Nordisk launched an $8.5 billion unsolicited bid for obesity drugmaker Metsera, topping Pfizer’s $7.3 billion agreed deal. Novo’s offer values Metsera at $56.50 per share in cash plus up to $21.25 in milestone payments. Metsera shares jumped 18% premarket, while Novo’s stock fell 3%. Pfizer called Novo’s bid “reckless” and warned it could harm competition.
30 October 2025
····
Merck (MRK) Stock Could Skyrocket: Key Drug Approvals & Analyst Targets Unveiled

Merck (MRK) Stock Dips on Earnings Beat — Will Pipeline Boost Spur a Rally?

Merck shares fell about 2% after hours Oct. 30 despite Q3 revenue of $17.28 billion and $2.58 adjusted EPS, both above estimates. Keytruda sales rose 10% to $8.1 billion. The company narrowed its 2025 sales outlook and raised profit guidance. Recent milestones include FDA approval of subcutaneous Keytruda and the $10 billion acquisition of Verona Pharma.
30 October 2025
···
1 … 33 34 35 36 37 38

Stock Market Today

  • Wheat Futures Mixed as Export Shipments Decline Week-over-Week
    April 11, 2026, 1:49 AM EDT. Wheat futures traded mixed Monday, with Chicago Soft Red Winter (SRW) contracts rising 1-2 cents, Kansas City Hard Red Winter (HRW) slipping slightly, and Minneapolis spring wheat down 1-3 cents. U.S. Export Inspections reported 337,685 metric tons (12.4 million bushels) of wheat shipped last week, down 16.2% from the previous week but 22.2% above last year's volume. Mexico and Thailand were top buyers. Marketing year shipments reach 12.283 million metric tons, 27.1% higher than last year. Precipitation outlook in the southern Plains remains limited, influencing market sentiment.

Latest article

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 11.04.2026

11 April 2026
LIVEMarkets rolling coverageStarted: April 11, 2026, 12:00 AM EDTUpdated: April 11, 2026, 2:02 AM EDT Wheat Futures Mixed as Export Shipments Decline Week-over-Week April 11, 2026, 1:49 AM EDT. Wheat futures traded mixed Monday, with Chicago Soft Red Winter (SRW) contracts rising 1-2 cents, Kansas City Hard Red Winter (HRW) slipping slightly, and Minneapolis spring wheat down 1-3 cents. U.S. Export Inspections reported 337,685 metric tons (12.4 million bushels) of wheat shipped last week, down 16.2% from the previous week but 22.2% above last year's volume. Mexico and Thailand were top buyers. Marketing year shipments reach 12.283 million metric tons,
UK Stock Market Today: FTSE 100 Climbs as Traders Eye Fragile Iran Ceasefire

UK Stock Market Today: FTSE 100 Climbs as Traders Eye Fragile Iran Ceasefire

10 April 2026
London’s FTSE 100 rose 0.38% to 10,644.28 late Friday morning as investors awaited U.S.-Iran talks in Pakistan. Brent crude climbed 1% to $96.83 a barrel, while sterling eased but was on track for its biggest weekly gain since January. The FTSE 250 gained 0.79%. Britain’s 10-year gilt yield stood at 4.807%.
US Stock Market Today: CPI, Oil and Iran Truce Set the Tone Before the Open

US Stock Market Today: CPI, Oil and Iran Truce Set the Tone Before the Open

10 April 2026
Dow e-minis slipped 0.15% before Friday’s open, with S&P 500 and Nasdaq 100 futures each down 0.08% as traders awaited March CPI data and watched U.S.-Iran tensions. Economists expect headline CPI to rise 0.9% for March and 3.3% year-on-year. Weekly jobless claims increased to 219,000. Brent crude traded near $97 a barrel, while shipping through the Strait of Hormuz remained well below normal.
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 10.04.2026

10 April 2026
LIVEMarkets rolling coverageStarted: April 10, 2026, 12:00 AM EDTUpdated: April 10, 2026, 11:59 PM EDT Orora ASX:ORA Faces Earnings Reset After Saverglass Impact and Middle East Disruptions April 10, 2026, 11:59 PM EDT. Orora (ASX:ORA) shares plunged over 8% in one day following a guidance update that revealed an earnings reset at its Saverglass unit due to Middle East supply chain disruptions and a shutdown at the Ras Al Khaimah glass plant. Despite a sharp short-term loss, Orora's 90-day share price rise exceeds 33%, contrasting a longer-term 10.58% annual total shareholder return decline amid ongoing sector pressures. Trading at A$1.49,
Go toTop